However, relying on reduced intake as a safety mechanism is unreliable
The cost depends entirely on your insurance status: Without Insurance: Wegovy retails at approximately $1,349/month
Therefore, semaglutide could improve other obesity-related pathologies like cardiovascular, hypertension, or fatty liver diseases
References: [1] The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease [2] [3] Novo Nordisk A/S: Semaglutide 2.4 mg reduces the risk of major adverse cardiovascular events by 20% in adults with overweight or obesity in the SELECT trial [4] STEP-HFpEF: Semaglutide Improves Symptoms, Physical Limitations, Weight Loss in Patients With HFpEF and Obesity
Advise the patient to read the FDA-approved patient labeling (Medication Guide)
Lower Inflammatory Markers : Reducing fat mass leads to lower levels of substances like high-sensitivity C-reactive protein (hs-CRP)